Severe spermatogenic failure (SF) affects nearly 1% of all men, accounting for approximately 20% of all cases of male infertility, and manifests as either scarcity (oligozoospermia) or absence (azoospermia) of sperm in ejaculate. Physicians are severely limited in their ability to offer useful direction for SF patients pertaining to the chances for successful treatment using assisted reproductive techniques (ART) and potential negative consequences in their ART-derived offspring because more than half of SF cases currently have no identifiable cause. Nonetheless, clinical members of our group have used genetic testing routinely in the management of male infertility for nearly a decade, as several Y chromosome microdeletions are known to be diagnostic of spermatogenic failure, and are prognostic for the success of surgical sperm retrieval. Over 1,000 genes are required for spermatogenesis in mammals, and over 200 mouse knockouts manifest SF;we hypothesize that over 20% of idiopathic SF cases are due to single-gene or oligogenic defects. We have recently published an array-based pilot study demonstrating that numerous genetic causes of SF remain to be discovered, and that recurrent deletions of the gene DMRT1 are a frequent, novel genetic cause of SF. In this proposal we describe experiments that will dramatically expand upon these findings to identify novel genetic causes of SF. We will perform whole exome sequencing of 1000 idiopathic azoospermic men, and 1000 control men with normal sperm concentrations. With these data we will produce an integrated map of genetic variants, using special computational and experimental reagents to enhance our analysis of the repeat-rich Y chromosome. We will perform a genomewide case-control analysis using untargeted variant and gene-based testing, as well as testing numerous biological hypotheses by aggregating variants into pathways or genomic annotations. We propose to use an efficient two-stage design to replicate the top 1% of associated variants and top 5% of associated genes. We have designed the stage I studies for maximum sensitivity to 3 distinct forms of SF mutations. In stage I(a) we re-use the control data generated as part of aim 1 to replicate common risk factors of moderate effect using a quantitative-trait analysis of sperm count. In stage I(b) we use an extreme phenotype sampling strategy to sample new patients from the top and bottom 10% of the sperm count distribution, maximizing our power to detect extremely rare monogenic/Mendelian variants of large effect. In stage I(c) we use existing genetic data from women with primary ovarian insufficiency (POI) to test for genes/genetic variants that modulate gonadal function in women as well as men. Variants of interest that are replicated in at least one of I(a,b,c) will then be taken forward for validation in a Chinese cohort of 3,000 azoospermic cases and 3,000 controls. In the short term, our findings will improve the ability of clinicians to use genetic data to counsel patients and improve patient care. In the long term, characterization of the genetic basis of spermatogenic failure could pave the way for the use of gene therapy strategies in azoospermic men.

Public Health Relevance

Despite its societal importance, and prevalence as high as 5-7%, the underlying etiology of male infertility is unknown in up to half of infertile men. With an improved understanding of the genetic causes of male infertility, patient genetic information will transform the way that male infertility is diagnosed and treated. Our international, multi- center study of male infertility genetics will build the resources necessary to bring male infertility car into the era of personalized genomic medicine.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
1R01HD078641-01A1
Application #
8777677
Study Section
Integrative and Clinical Endocrinology and Reproduction Study Section (ICER)
Program Officer
Moss, Stuart B
Project Start
2014-09-10
Project End
2019-05-30
Budget Start
2014-09-10
Budget End
2015-05-30
Support Year
1
Fiscal Year
2014
Total Cost
$691,934
Indirect Cost
$147,974
Name
Washington University
Department
Genetics
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Nagirnaja, Liina; Aston, Kenneth I; Conrad, Donald F (2018) Genetic intersection of male infertility and cancer. Fertil Steril 109:20-26
Kasak, Laura; Punab, Margus; Nagirnaja, Liina et al. (2018) Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia. Am J Hum Genet 103:200-212
Joshi, Nikhil; Chan, Jessica L (2017) Female Genomics: Infertility and Overall Health. Semin Reprod Med 35:217-224
Lima, Ana C; Conrad, Donald F (2017) The long and short of translational control in male germ cells. Biol Reprod 97:2-4
Lima, Ana C; Jung, Min; Rusch, Jannette et al. (2017) A Standardized Approach for Multispecies Purification of Mammalian Male Germ Cells by Mechanical Tissue Dissociation and Flow Cytometry. J Vis Exp :
Ho, Nicholas R Y; Usmani, Abul R; Yin, Yan et al. (2017) Multiplex shRNA Screening of Germ Cell Development by in Vivo Transfection of Mouse Testis. G3 (Bethesda) 7:247-255
Lima, Ana C; Jung, Min; Rusch, Jannette et al. (2016) Multispecies Purification of Testicular Germ Cells. Biol Reprod 95:85
Wilfert, Amy B; Chao, Katherine R; Kaushal, Madhurima et al. (2016) Genome-wide significance testing of variation from single case exomes. Nat Genet 48:1455-1461
Huang, Ni; Wen, Yang; Guo, Xuejiang et al. (2015) A Screen for Genomic Disorders of Infertility Identifies MAST2 Duplications Associated with Nonobstructive Azoospermia in Humans. Biol Reprod 93:61
Ho, N R Y; Huang, N; Conrad, D F (2015) Improved detection of disease-associated variation by sex-specific characterization and prediction of genes required for fertility. Andrology 3:1140-9

Showing the most recent 10 out of 12 publications